Warning: Cannot modify header information - headers already sent by (output started at /home4/theeurek/public_html/amcrasto/wp-config.php:1) in /home4/theeurek/public_html/amcrasto/wp-includes/rest-api/class-wp-rest-server.php on line 1831

Warning: Cannot modify header information - headers already sent by (output started at /home4/theeurek/public_html/amcrasto/wp-config.php:1) in /home4/theeurek/public_html/amcrasto/wp-includes/rest-api/class-wp-rest-server.php on line 1831

Warning: Cannot modify header information - headers already sent by (output started at /home4/theeurek/public_html/amcrasto/wp-config.php:1) in /home4/theeurek/public_html/amcrasto/wp-includes/rest-api/class-wp-rest-server.php on line 1831

Warning: Cannot modify header information - headers already sent by (output started at /home4/theeurek/public_html/amcrasto/wp-config.php:1) in /home4/theeurek/public_html/amcrasto/wp-includes/rest-api/class-wp-rest-server.php on line 1831

Warning: Cannot modify header information - headers already sent by (output started at /home4/theeurek/public_html/amcrasto/wp-config.php:1) in /home4/theeurek/public_html/amcrasto/wp-includes/rest-api/class-wp-rest-server.php on line 1831

Warning: Cannot modify header information - headers already sent by (output started at /home4/theeurek/public_html/amcrasto/wp-config.php:1) in /home4/theeurek/public_html/amcrasto/wp-includes/rest-api/class-wp-rest-server.php on line 1831

Warning: Cannot modify header information - headers already sent by (output started at /home4/theeurek/public_html/amcrasto/wp-config.php:1) in /home4/theeurek/public_html/amcrasto/wp-includes/rest-api/class-wp-rest-server.php on line 1831

Warning: Cannot modify header information - headers already sent by (output started at /home4/theeurek/public_html/amcrasto/wp-config.php:1) in /home4/theeurek/public_html/amcrasto/wp-includes/rest-api/class-wp-rest-server.php on line 1831
{"id":470,"date":"2013-01-09T10:05:04","date_gmt":"2013-01-09T10:05:04","guid":{"rendered":"http:\/\/amcrasto.theeurekamoments.com\/?p=470"},"modified":"2013-01-10T05:19:03","modified_gmt":"2013-01-10T05:19:03","slug":"lm11a-31-new-drug-can-help-paralyzed-people-walk-again","status":"publish","type":"post","link":"https:\/\/amcrasto.theeurekamoments.com\/2013\/01\/09\/lm11a-31-new-drug-can-help-paralyzed-people-walk-again\/","title":{"rendered":"LM11A-31, New drug can help paralyzed people walk again"},"content":{"rendered":"

\"Figure<\/a><\/p>\n

 <\/p>\n

LM11A-31, C12<\/sub> H25<\/sub> N3<\/sub> O2,<\/sub> Pentanamide, 2-amino-3-methyl-N<\/em>–[2-(4-morpholinyl)ethyl]– WO 2010102212 TO LONGO FRANK, PUB 10.09.2010 THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL<\/strong><\/wbr><\/wbr><\/wbr><\/wbr><\/wbr><\/wbr><\/wbr><\/wbr><\/wbr><\/p>\n\n\n\n
PATENT LINK<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u00a0http:\/\/patentscope.wipo.int\/search\/en\/WO2010102212<\/a><\/p>\n

Scientists have developed a pill which they claim could help paralyzed people walk again.<\/p>\n

The new drug allowed mice with no movement in their lower limbs to walk with ‘well-coordinated steps’ and even to replicate swimming motions, researchers said.<\/p>\n

The experimental drug, called LM11A-31, was developed by Professor Frank Longo, of Stanford University, California.<\/p>\n

The researchers gave three different oral doses of LM11A-31, as well as a placebo, to different groups of mice beginning four hours after injury and then twice daily for a 42 day experimental period, the ‘Daily Mail’ reported.<\/p>\n

In tests, the experimental medication did not increase pain in the mice and showed no toxic effects on the animals.<\/p>\n

It also efficiently crossed the blood brain barrier, which protects the central nervous system from potentially harmful chemicals carried around in the rest of the bloodstream.<\/p>\n

An injury to the spinal cord stops the brain controlling the body and this is the first time an oral drug has been shown to provide an effective therapy.<\/p>\n

“This is a first to have a drug that can be taken orally to produce functional improvement with no toxicity in a rodent model,” Professor Sung Ok Yoon, of Ohio State University, Columbus, said.<\/p>\n

“So far, in the spinal cord injury field with rodent models, effective treatments have included more than one therapy, often involving invasive means. Here, with a single agent, we were able to obtain functional improvement,” Yoon said.<\/p>\n

The small molecule in the study was tested for its ability to prevent the death of cells called oligodendrocytes.<\/p>\n

These cells surround and protect axons, long projections of a nerve cell, by wrapping them in a myelin sheath that protect the fibres.<\/p>\n

In addition to functioning as axon insulation, myelin allows for the rapid transmission of signals between nerve cells.<\/p>\n

The drug preserved oligodendrocytes by inhibiting the activation of a protein called p75. Yoon’s lab previously found p75 is linked to the death of these specialised cells after a spinal cord injury. When they die, axons that are supported by them degenerate.<\/p>\n

“Because we know oligodendrocytes continue to die for a long period of time after an injury, we took the approach that if we could put a brake on that cell death, we could prevent continued degeneration of axons,” she said.<\/p>\n

Full Text – Journal of Neuroscience<\/a><\/h3>\n
http:\/\/www.jneurosci.org\/content\/26\/20\/5288.full<\/cite><\/a><\/div>\n

Small, Nonpeptide p75NTR<\/sup> Ligands Induce Survival Signaling and Inhibit proNGF-Induced Death\u00a0 in Journal of neuroscience, 26(20): 5288-5300; doi: 10.1523\/\u200bJNEUROSCI.3547-05.2006 <\/cite>by SM Massa – 2006 – Cited by 51<\/a> – Related articles<\/a>
\n17 May 2006 \u2013 At 5 nm, LM11A-24 and -31 inhibit TUNEL staining to a degree …<\/strong> We further prioritized LM11A<\/em>–31<\/em>, because preliminary studies<\/p>\n

Small, Nonpeptide p75NTR<\/sup> Ligands Induce Survival Signaling and Inhibit proNGF-Induced Death<\/h1>\n

\"Figure<\/a><\/p>\n

2010 slide presentation re p75 (e.g. LM11A<\/em>–31<\/em>) by PharmatrophiX’s …<\/strong><\/a><\/h3>\n
investorvillage.com\/smbd.asp?mb=160&mn=440341…<\/cite><\/div>\n

3 Nov 2010 \u2013 2010 slide presentation re p75 (e.g. LM11A<\/em>–31<\/em>) by PharmatrophiX’s founder. Longo is PharmatrophiX’s founder. <\/strong><\/p>\n

\"TheThe experimental drug was developed by Prof Frank Longo from Stanford University<\/div>\n
\n